NCT05263921View on ClinicalTrials.gov

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Bioavailability
Interventions
DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions

Trial Locations (1)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05263921 - Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants | Biotech Hunter | Biotech Hunter